The ESCMID Vaccine Study Group (EVASG) is at the forefront of vaccine research and education. Gathering experts aiming to promote advancement in the field of vaccination, covering public health to special populations, their mission is to:
Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1).
Beraud G, Bouetard L, Civljak R, Michon J, Tulek N, Lejeune S, Millot R, Garchet-Beaudron A, Lefebvre M, Veliko P, Festou B, Abgrall S, Lizatovic I K, Baldolli A, Esme H, Blanch S, Froidevaux G, Kapincheva N, Faucher JF, Duvnjak M, Afşar E, Švitek L, Yarimoglu S, Yarimoglu R, Janssen C, Epaulard O, on behalf of EVASG. Clin Microbiol Infect. 2023;29(5):642–650.
Exclusion of older adults and immunocompromised individuals in influenza, pneumococcal and COVID-19 vaccine trials before and after the COVID-19 pandemic.
Bukan K, Pearce-Slade T, Eiberg M, Tinelli M, Yahav D, Tuells J, Epaulard O, Holler JG, Roed C, Søborg C, Jensen Stæhr JU, Barrella Harboe Z. Aging Clin Exp Res. 2023;35(5):917–923.
If you have questions or comments for our study group, we warmly invite you to contact us!